94 related articles for article (PubMed ID: 20186950)
1. In response to "a gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system".
Raybon JJ; Albright CF
Ann Neurol; 2010 Jan; 67(1):143-4; author reply 144-5. PubMed ID: 20186950
[No Abstract] [Full Text] [Related]
2. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.
Siemers ER; Dean RA; Friedrich S; Ferguson-Sells L; Gonzales C; Farlow MR; May PC
Clin Neuropharmacol; 2007; 30(6):317-25. PubMed ID: 18090456
[TBL] [Abstract][Full Text] [Related]
5. Molecule of the month. Semagacestat.
Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
[No Abstract] [Full Text] [Related]
6. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
Lanz TA; Karmilowicz MJ; Wood KM; Pozdnyakov N; Du P; Piotrowski MA; Brown TM; Nolan CE; Richter KE; Finley JE; Fei Q; Ebbinghaus CF; Chen YL; Spracklin DK; Tate B; Geoghegan KF; Lau LF; Auperin DD; Schachter JB
J Pharmacol Exp Ther; 2006 Nov; 319(2):924-33. PubMed ID: 16920992
[TBL] [Abstract][Full Text] [Related]
7. Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.
Peters JU; Galley G; Jacobsen H; Czech C; David-Pierson P; Kitas EA; Ozmen L
Bioorg Med Chem Lett; 2007 Nov; 17(21):5918-23. PubMed ID: 17869099
[TBL] [Abstract][Full Text] [Related]
8. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
Lanz TA; Hosley JD; Adams WJ; Merchant KM
J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
11. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
[TBL] [Abstract][Full Text] [Related]
12. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
13. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.
Du P; Wood KM; Rosner MH; Cunningham D; Tate B; Geoghegan KF
J Pharmacol Exp Ther; 2007 Mar; 320(3):1144-52. PubMed ID: 17202404
[TBL] [Abstract][Full Text] [Related]
14. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.
Bateman RJ; Siemers ER; Mawuenyega KG; Wen G; Browning KR; Sigurdson WC; Yarasheski KE; Friedrich SW; Demattos RB; May PC; Paul SM; Holtzman DM
Ann Neurol; 2009 Jul; 66(1):48-54. PubMed ID: 19360898
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
17. pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.
Sozio P; Rapino M; Di Valerio V; Laserra S; Pacella S; Di Stefano A; Cataldi A
J Biol Regul Homeost Agents; 2012; 26(2):245-51. PubMed ID: 22824752
[TBL] [Abstract][Full Text] [Related]
18. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
19. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Schor NF
Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
[TBL] [Abstract][Full Text] [Related]
20. PEN-2 enhances gamma-cleavage after presenilin heterodimer formation.
Shiraishi H; Sai X; Wang HQ; Maeda Y; Kurono Y; Nishimura M; Yanagisawa K; Komano H
J Neurochem; 2004 Sep; 90(6):1402-13. PubMed ID: 15341524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
